| Project item | Indications | Research phase | Cooperation demands |
| BDA202203 | B7H3+ and PD-L1+/low cancer | CMC development | License-out or co-development |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBS-K040 | Human | Human B7-H3(4Ig)-coupled Magnetic Beads |
|
||
| B73-C52Ha | Cynomolgus | Cynomolgus B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-H82F5 | Human | Biotinylated Human B7-H3 / CD276 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| B73-H82E6 | Human | Biotinylated Human B7-H3 / CD276 Protein, Avitag™,His Tag |  |
|
|
| B73-M52H4 | Mouse | Mouse B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-M5255 | Mouse | Mouse B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |
|
|
| B73-H52E2 | Human | Human B7-H3 / CD276 Protein, His Tag (MALS verified) |  |
|
|
| B73-H5253 | Human | Human B7-H3 / CD276 Protein, Fc Tag (MALS verified) |  |
|
|
Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) is more than 90% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.
Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Monoclonal antibody 8H9 I-124 | 124I-8H9; 124I-8H9-(B7-H3) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Glioma | Details |
| SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Central Nervous System Neoplasms; Glioma | Details |
| 4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
| Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics | Head and Neck Neoplasms; Rhabdomyosarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Desmoplastic Small Round Cell Tumor; Carcinoma, Renal Cell; Wilms Tumor; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Urethral Neoplasms; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| MGC-018 | MGC-018 | Phase 2 Clinical | Macrogenics | Neoplasms | Details |
| Monoclonal antibody 8H9 I-131 | 8H9-MAb; 131-I-8H9; 131I-8H9-(B7-H3) | Phase 3 Clinical | Memorial Sloan Kettering Cancer Center | Neuroblastoma; Peritoneal Neoplasms; Central Nervous System Diseases; Neoplasm Metastasis | Details |
| B7-H3 CAR-T cell therapy (Zhejiang University) | Phase 2 Clinical | Zhejiang University Alumni Association (Singapore) | Glioblastoma | Details | |
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics | Sarcoma, Synovial; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Neuroblastoma; Neurofibrosarcoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma | Details |
| DS-7300 | DS-7300 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours | Details |
| Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
| Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Hematologic Neoplasms; Solid tumours | Details |
| Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms | Details |
| Omburtamab I-131 | Phase 1 Clinical | Y-Mabs | Central Nervous System Neoplasms; Sarcoma; Neuroblastoma; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
| 177Lu-DTPA-omburtamab | Phase 2 Clinical | Y-Mabs | Solid tumours; Meningeal Neoplasms | Details | |
| B7-H3-targeting CAR-T cell therapy (Beijing Tiantan Hospital, Capital Medical University) | Beijing Tiantan Hospital, Capital Medical University | Details |
This web search service is supported by Google Inc.
A-Z
